Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
McKinsey
Moodys
Harvard Business School
Colorcon

Last Updated: May 26, 2022

TREXIMET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Treximet patents expire, and when can generic versions of Treximet launch?

Treximet is a drug marketed by Currax and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has sixteen patent family members in fourteen countries.

The generic ingredient in TREXIMET is naproxen sodium; sumatriptan succinate. There are forty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the naproxen sodium; sumatriptan succinate profile page.

DrugPatentWatch® Generic Entry Outlook for Treximet

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Paragraph IV (Patent) Challenges for TREXIMET
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TREXIMET Tablets naproxen sodium; sumatriptan succinate 500 mg/85 mg 021926 1 2008-07-23

US Patents and Regulatory Information for TREXIMET

TREXIMET is protected by one US patents.

Patents protecting TREXIMET

Multilayer dosage forms containing NSAIDs and triptans
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TREXIMET

International Patents for TREXIMET

When does loss-of-exclusivity occur for TREXIMET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 03303631
Estimated Expiration: See Plans and Pricing

Austria

Patent: 6134
Estimated Expiration: See Plans and Pricing

Canada

Patent: 09023
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 12640
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 75566
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 75566
Estimated Expiration: See Plans and Pricing

Israel

Patent: 9041
Estimated Expiration: See Plans and Pricing

Japan

Patent: 16009
Estimated Expiration: See Plans and Pricing

Patent: 06515856
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 05006954
Estimated Expiration: See Plans and Pricing

Norway

Patent: 6458
Estimated Expiration: See Plans and Pricing

Patent: 053193
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 75566
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 75566
Estimated Expiration: See Plans and Pricing

Spain

Patent: 80827
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TREXIMET around the world.

Country Patent Number Title Estimated Expiration
Spain 8801788 See Plans and Pricing
Egypt 17283 AN INDOLE DERIVATIVE See Plans and Pricing
Spain 8801204 See Plans and Pricing
Australia 573878 See Plans and Pricing
Spain 557480 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TREXIMET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900 2011/016 Ireland See Plans and Pricing PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900 2011C/016 Belgium See Plans and Pricing PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1411900 SPC/GB11/015 United Kingdom See Plans and Pricing PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900 18/2011 Austria See Plans and Pricing PRODUCT NAME: NAPROXEN UND ESOMEPRAZOL SOWIE DEREN PHARMAZEUTISCH ANNEHMBARE SALZE; NAT. REGISTRATION NO/DATE: 1-29937 20110105; FIRST REGISTRATION: GB PL 17901/0263-0001 20101105
1411900 122012000052 Germany See Plans and Pricing PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Baxter
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.